MARKET

IMMU

IMMU

Immunomedics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

40.63
+3.09
+8.23%
Closed 19:29 07/06 EDT
OPEN
39.88
PREV CLOSE
37.54
HIGH
41.40
LOW
39.22
VOLUME
6.64M
TURNOVER
--
52 WEEK HIGH
37.69
52 WEEK LOW
8.80
MARKET CAP
9.38B
P/E (TTM)
-22.2948
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IMMU stock price target is 45.87 with a high estimate of 55.00 and a low estimate of 31.00.

EPS

IMMU News

More
Immunomedics' Shares Surge YTD on Cancer Drug Approval
Zacks · 16h ago
Shares of Immunomedics jump on positive confirmatory data for its breast-cancer drug
Shares of Immunomedics Inc. gained 6.9% in trading on Monday after the drugmaker said a confirmatory Phase 3 clinical trial of its breast-cancer drug Trodelvy met its primary and secondary endpoints. The Food and Drug Administration in April had approved Trod
MarketWatch · 17h ago
Immunomedics shares are trading higher after the company's phase 3 breast cancer ASCENT study of Trodelvy met its primary endpoint.
Benzinga · 19h ago
Immunomedics Shares Resume Trade
Benzinga · 20h ago
Immunomedics Announces Phase 3 ASCENT Study Of Trodelvy Met Its Primary Endpoint
Trodelvy significantly improved progression-free survival (PFS) and overall survival (OS) in previously-treated brain metastasis negative patients with advanced mTNBC The safety profile of Trodelvy was consistent with
Benzinga · 20h ago
Immunomedics Announces Positive Results from Phase 3 ASCENT Study of TRODELVY™ in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer (mTNBC)
Trodelvy significantly improved progression-free survival (PFS) and overall survival (OS) in previously-treated brain metastasis negative patients with advanced mTNBC The.
GlobeNewswire · 20h ago
Immunomedics Shares Halted, News Pending
Benzinga · 20h ago
Immunomedics' Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Immunomedics.
Zacks · 21h ago

Industry

Biotechnology & Medical Research
+0.67%
Pharmaceuticals & Medical Research
+0.72%

Hot Stocks

Symbol
Price
%Change

About IMMU

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of six clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130). The Company also has a range of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various-stages of clinical and pre-clinical development.
More

Webull offers kinds of Immunomedics, Inc. stock information, including NASDAQ:IMMU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMU stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMMU stock methods without spending real money on the virtual paper trading platform.